INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Biogen Inc. & Encourages Investors with Los...
October 26 2016 - 2:31PM
Business Wire
Goldberg Law PC, a national shareholder rights litigation firm,
announces the filing of a class action lawsuit against Biogen Inc.
(“Biogen” or the “Company”) (Nasdaq: BIIB). Investors who purchased
or otherwise acquired Biogen shares between July 23, 2014 and July
23, 2015 inclusive (the “Class Period”) are encouraged to contact
the firm in advance of the December 23, 2016
lead plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class
Period, click here to participate. In addition, we encourage
you to contact Michael Goldberg or Brian Schall, of Goldberg Law
PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at
800-977-7401, to discuss your rights free of charge. You can also
reach us through the firm’s website at
http://www.Goldberglawpc.com, or by email at
info@goldberglawpc.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
The complaint alleges that during the Class Period, Biogen
issued false and misleading statements concerning the safety
profile and growth prospects of Tecfidera, an immunosuppressant
that is prescribed to treat multiple sclerosis (“MS”), and Biogen’s
main driver of revenues at the time. The Company publicly praised
Tecfidera’s attractive safety profile and solid growth trajectory,
while aware that the drug weakened the immune system for MS
patients, causing physicians to discontinue prescriptions of
Tecfidera. On October 22, 2014, Biogen announced the death of a
patient linked to Tecfidera. On April 24, 2015, the Company
disclosed that the patient death announced in October 2014 was
causing Tecfidera sales to grow “at an overall slower rate” but the
long-term outlook “remain[ed] strong.” On July 24, 2015, Biogen
abruptly cut its revenue guidance in half due to a revised growth
expectation for Tecfidera based on safety concerns following the
patient death. When this news was announced, shares of Biogen fell
in value, causing investors harm.
Goldberg Law PC represents shareholders around the world and
specializes in securities class actions and shareholder rights
litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161026006628/en/
Goldberg Law PC, Los AngelesMichael Goldberg, Esq.,
800-977-7401Brian Schall, Esq.,
800-977-7401info@goldberglawpc.comwww.Goldberglawpc.com
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Sep 2023 to Sep 2024